VANCOUVER, Oct. 24 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , will webcast its conference call discussing financial results for the third quarter ended September 30, 2005 on Thursday, November 3rd, 2005 at 2:00 PM PST (5:00 PM EST).
The webcast will be available to all interested parties through Angiotech's website at www.angiotech.com under Investor Relations or by dialing toll-free in North America to 866-383-8108 (International callers please dial 617-597-5343) and entering Passcode 27335122. To ensure a timely connection to the webcast it is recommended that users register approximately 15 minutes before the conference call. A recording of the call will be available until Thursday, November 10, 2005 by dialing toll-free in North America 888-286-8010 (International at 617-801-6888) and entering Passcode 50587442. A press release will be issued prior to the conference call.
The conference call will be hosted by William Hunter, President and Chief Executive Officer, and David Hall, Chief Financial Officer.
The webcast will be available for seven days on the Angiotech website.
Vancouver-based Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical company pioneering the combination of pharmaceutical compounds with medical devices and biomaterials to both create novel solutions for poorly addressed disease states and dramatically improve surgical outcomes. To find out more about Angiotech Pharmaceuticals, Inc. , please visit our website at www.angiotech.com
FOR ADDITIONAL INFORMATION: --------------------------- Analysts and Investors: Todd Young, Vice President Investor Relations and Communications, Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext 6933 Analysts: Rui Avelar, Senior Vice President Medical Affairs and Communications, Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext 6996 Media: Wendy Carhart, Waggener Edstrom Bioscience, (503) 443-7354, Email: wendyc@wagged.com
Angiotech Pharmaceuticals, Inc.CONTACT: Analysts and Investors: Todd Young, Vice President InvestorRelations and Communications, Angiotech Pharmaceuticals, Inc., (604)221-7676 ext 6933; Analysts: Rui Avelar, Senior Vice President MedicalAffairs and Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7676ext 6996; Media: Wendy Carhart, Waggener Edstrom Bioscience, (503)443-7354, Email: wendyc@wagged.com
